Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Humacyte. The associated price target remains the same with $3.50.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Josh Jennings has given his Buy rating due to a combination of factors that highlight the promising potential of Humacyte’s Symvess product. The recent publication in Military Medicine underscores the long-term effectiveness of Symvess in treating complex wartime injuries, showing a high rate of patency and complete limb salvage with no infections after 18 months. This data reinforces the product’s durability and efficacy in challenging conditions.
Moreover, Symvess’s FDA approval for vascular trauma, supported by strong trial results, further strengthens its market position. The trials demonstrated excellent outcomes, including high patency rates and zero infection, which are crucial for its success in real-world applications. These positive indicators contribute to Jennings’s confidence in Humacyte’s growth prospects, justifying the Buy rating.